Company news
Bionexus Gene Lab Corp (NASDAQ:BGLC) news
Bionexus Gene Lab Corp news releases on 6ix. Latest, Oct 5, 2026: RYET to Enter Malaysian Healthcare Through Exclusive Cogni AI License to BioNexus Gene Lab
Press releases & updates
RYET to Enter Malaysian Healthcare Through Exclusive Cogni AI License to BioNexus Gene Lab
October 4, 2026
BioNexus Advances VitaGuard™ Southeast Asia Rollout Following China Working Visit
July 27, 2026
BioNexus Gene Lab Corp. Calls for Malaysia–China Biotechnology Cooperation to Move Beyond Trade into Co-Development
May 28, 2026
BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard™ MRD Platform
March 10, 2026
BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman
February 23, 2026
BioNexus Launches Regional Deployment of VitaGuard™ MRD Infrastructure; Positioned to Challenge Legacy Oncology Platforms Across ASEAN’s Multi-Billion Dollar Market
January 28, 2026
BioNexus Gene Lab Corp. Completes Strategic Investment in Fidelion Diagnostics; Secures 15% Equity Stake in Global AI-Oncology Platform and Exclusive Southeast Asian Rights for VitaGuard™
December 3, 2025
BioNexus Gene Lab Corp. (Nasdaq: BGLC) Secures $500 Million Equity Facility From ARC Group International to Support Expansion of Precision Diagnostics, CDMO Operations, and Therapeutic Commercialization
December 2, 2025
BioNexus Gene Lab Corp. (Nasdaq: BGLC) and Fidelion Diagnostics Execute Exclusive Southeast Asia License for VitaGuard™ MRD Platform as Part of Strategic Alliance with Tongshu Gene
December 1, 2025
BioNexus Gene Lab Corp. (Nasdaq: BGLC) Announces Strategic Agreements with Fidelion Diagnostics for Southeast Asia MRD Commercialization
November 12, 2025
BioNexus Gene Lab Corp. Files $100 Million Shelf Registration and Establishes $20 Million At-the-Market Program to Advance Strategic Growth Opportunities
November 10, 2025
BioNexus Gene Lab Corp Signs Strategic Partnership Term Sheet with BirchBioMed Inc.
October 19, 2025
BioNexus Gene Lab Corp. and Fidelion Diagnostics Announce Landmark Alliance—Touted as a new “DeepSeek Moment” in Precision Oncology
July 30, 2025
BioNexus Gene Lab Corp. Regains Nasdaq Compliance, Signaling Strategic Stability and Growth Readiness
April 30, 2025
BioNexus Gene Lab Corp. Files 2024 Annual Report Highlighting Strategic Innovation, Operational Resilience, and Growth Trajectory
April 15, 2025
BioNexus Gene Lab Corp. Announces Board Approval of Ethereum Treasury Strategy and Release of Strategic Whitepaper
March 5, 2025
BioNexus Gene Lab Corporation announces entry into Biogas Sector via Teaming Agreement with Protech Builders Sdn. Bhd.
September 24, 2024
BioNexus Gene Lab Corp. Signs Strategic Outsourcing Agreement with VITARRAY Global Pte. Ltd.
September 13, 2024
BioNexus Gene Lab Corp. Signs Strategic Partnership MOU with Shenzhen Rongguang Group to Advance Cancer Screening, Precision Medicine, and Preventative Healthcare Solutions
September 12, 2024
BioNexus Gene Lab Corp Announces New Business Developments for Subsidiary Chemrex with Investment in High-Quality Color Paste Production
September 10, 2024
BioNexus Gene Lab Corp. Completes Strategic RM 1 Million Investment in Ascension Innovation Sdn Bhd
August 26, 2024
BioNexus Gene Lab Corp. Announces Successful Securities Commission of Malaysia (MyCIF) Co-Investment in Ascension Innovation Sdn Bhd
August 26, 2024
BioNexus Gene Lab Corp. Agrees to Invest RM 1.2 million in Ascension Innovation (AISB) to Advance Digital Health Innovation through AI adoption in Healthcare
April 18, 2024
BioNexus Gene Lab : Agrees to Invest RM 1.2 million in Ascension Innovation (AISB) to Advance Digital Health Innovation through AI adoption in Healthcare - Form 8-K
April 18, 2024
BioNexus Gene Lab : Submission of Matters to a Vote of Security Holders - Form 8-K
April 1, 2024
BioNexus Gene Lab Corp. Announces Closing of $5.75 Million Public Offering and Full Exercise of Over-Allotment Option and Uplisting to the Nasdaq Capital Market
July 23, 2023
BioNexus Gene Lab Corp. Announces Pricing of $5 Million Public Offering and Uplisting to the Nasdaq Capital Market
July 19, 2023